BTIG Research Reaffirms "Buy" Rating for Tiziana Life Sciences (NASDAQ:TLSA)

Key Points

• BTIG Research reaffirmed its “Buy” rating on Tiziana Life Sciences, although the broader analyst consensus remains “Hold,” with one Buy, one Hold, and one Sell rating.
• TLSA shares opened at $0.90, below their 50-day moving average of $1.01 and 200-day moving average of $1.19; the stock’s 12-month range is $0.76 to $2.35.
• Insiders have been buying shares, including CEO Ivor Elrifi’s purchase of 237,616 shares, while Mid American Wealth Advisory Group disclosed a new 323,240-share position.

Tiziana Life Sciences (NASDAQ:TLSA - Get Free Report)'s stock had its "buy" rating reissued by investment analysts at BTIG Research in a report issued on Tuesday, Benzinga reports.

Other analysts have also recently issued reports about the stock. Zacks Research upgraded shares of Tiziana Life Sciences to a "hold" rating in a report on Tuesday, July 14th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Tiziana Life Sciences in a report on Wednesday, August 26th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold".

Tiziana Life Sciences Stock Down 0.1%

Shares of TLSA opened at $0.90 on Tuesday. The firm's 50 day moving average is $1.01 and its 200-day moving average is $1.19. Tiziana Life Sciences has a 12-month low of $0.76 and a 12-month high of $2.35.

Insider Activity at Tiziana Life Sciences

In other Tiziana Life Sciences news, CEO Ivor Elrifi purchased 237,616 shares of the stock in a transaction dated Wednesday, August 5th. The shares were acquired at an average price of $1.00 per share, for a total transaction of $237,616.00. Following the completion of the acquisition, the chief executive officer owned 4,793,684 shares of the company's stock, valued at $4,793,684. This represents a 5.22% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders acquired a total of 988,423 shares of company stock valued at $985,909 over the last ninety days. Company insiders own 39.82% of the company's stock.

Institutional Investors Weigh In On Tiziana Life Sciences

An institutional investor recently bought a new stake in Tiziana Life Sciences stock. Mid American Wealth Advisory Group Inc. acquired a new stake in shares of Tiziana Life Sciences Ltd (NASDAQ:TLSA - Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 323,240 shares of the company's stock, valued at approximately $414,000. Mid American Wealth Advisory Group Inc. owned approximately 0.25% of Tiziana Life Sciences as of its most recent filing with the Securities & Exchange Commission.

About Tiziana Life Sciences

Tiziana Life Sciences Ltd. NASDAQ: TLSA is a clinical-stage biotechnology company developing therapeutics for neuroinflammatory and autoimmune diseases. The company's lead product candidate is foralumab, a fully human monoclonal antibody that targets the CD3 receptor on T cells and is being developed in an intranasal formulation designed to modulate immune activity.

Tiziana has evaluated foralumab in clinical research involving non-active secondary progressive multiple sclerosis and has also investigated its potential in conditions involving neuroinflammation, including Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.